{"id":8396,"date":"2025-08-20T13:30:13","date_gmt":"2025-08-20T10:30:13","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8396"},"modified":"2025-08-20T13:36:23","modified_gmt":"2025-08-20T10:36:23","slug":"early-rhythm-control-erc-in-atrial-fibrillation-evidence-guideline-summary-source-jama-cardiol","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/early-rhythm-control-erc-in-atrial-fibrillation-evidence-guideline-summary-source-jama-cardiol\/","title":{"rendered":"Early Rhythm Control (ERC) in Atrial Fibrillation \u2013 Evidence & Guideline Summary"},"content":{"rendered":"
Early Rhythm Control (ERC) in Atrial Fibrillation \u2013 Evidence & Guideline Summary<\/div>\n
Source : JAMA Cardiol<\/div>\n
Published Online: July 30, 2025<\/div>\n
<\/div>\n
1. Scientific Evidence<\/div>\n
\u2022 EAST-AFNET 4 Trial (NEJM 2020):<\/span><\/div>\n
\u2022 Enrolled patients with newly diagnosed AF (\u226412 months).<\/span><\/div>\n
\u2022 Compared Early Rhythm Control (ERC) (antiarrhythmic drugs, ablation, or cardioversion) vs Usual Care (mainly rate control).<\/span><\/div>\n
\u2022 Showed significant reduction in:<\/span><\/div>\n
\u2022 Stroke<\/span><\/div>\n
\u2022 Cardiovascular death<\/span><\/div>\n
\u2022 Hospitalization due to heart failure or acute coronary syndrome.<\/span><\/div>\n
\u2022 Sub-analyses (JAMA Cardiol 2025, etc.):<\/span><\/div>\n
\u2022 Benefit of ERC is consistent in high-risk groups, including:<\/span><\/div>\n
\u2022 Patients with obesity<\/span><\/div>\n
\u2022 Patients with diabetes<\/span><\/div>\n
\u2022 Older adults (mean age ~70 in trial).<\/span><\/div>\n
\u2022 Neither obesity nor diabetes should be a reason to withhold ERC.<\/span><\/div>\n
<\/div>\n
2. ESC 2020 AF Guidelines \u2013 Position on ERC<\/div>\n
\u2022 ERC in newly diagnosed AF (\u226412 months):<\/span><\/div>\n
\u2022 Class IIa, Level of Evidence B<\/span><\/div>\n
\u2022 Meaning: \u201cshould be considered\u201d but not yet a Class I recommendation because evidence comes mainly from one large RCT (EAST-AFNET 4), not multiple confirmatory RCTs.<\/span><\/div>\n
<\/div>\n
3. Class I Indications for Rhythm Control (Strong Recommendations)<\/div>\n
<\/div>\n
According to ESC 2020 AF Guidelines:<\/div>\n
\u2022 Symptomatic AF<\/span><\/div>\n
\u2022 Rhythm control is Class I if symptoms persist despite adequate rate control.<\/span><\/div>\n
\u2022 Heart Failure with Reduced Ejection Fraction (HFrEF, LVEF \u226440%)<\/span><\/div>\n
\u2022 Rhythm control (especially catheter ablation) is Class I because it improves symptoms and cardiac function.<\/span><\/div>\n
\u2022 Tachycardia-induced Cardiomyopathy<\/span><\/div>\n
\u2022 Rhythm control is Class I to reverse LV dysfunction and restore normal cardiac performance.<\/span><\/div>\n
\u2022 Post-ablation recurrence (if symptomatic):<\/span><\/div>\n
\u2022 Re-attempt at rhythm control is Class I in selected patients.<\/span><\/div>\n
<\/div>\n
4. Practical Clinical Takeaways<\/div>\n
\u2022 Newly Diagnosed AF:<\/span><\/div>\n
\u2022 ERC should be considered early (Class IIa) for all, not just symptomatic patients, based on EAST-AFNET 4.<\/span><\/div>\n
\u2022 Do NOT delay ERC in high-risk groups:<\/span><\/div>\n
\u2022 Obese patients, diabetics, elderly patients \u2013 all benefit equally from early intervention.<\/span><\/div>\n
\u2022 Clear-cut Class I cases (strongest recommendation):<\/span><\/div>\n
\u2022 Symptomatic AF refractory to rate control.<\/span><\/div>\n
\u2022 AF with HFrEF (LVEF \u226440%).<\/span><\/div>\n
\u2022 Tachycardia-induced cardiomyopathy.<\/span><\/div>\n
\u2022 Symptomatic AF recurrence after ablation.<\/span><\/div>\n
<\/div>\n
In summary:<\/div>\n
\u2022 ERC is safe and effective in newly diagnosed AF patients, with or without obesity\/diabetes (Class IIa, Level .<\/span><\/div>\n
\u2022 Strong Class I recommendation for rhythm control applies only to symptomatic AF, AF with HFrEF, tachycardia-induced cardiomyopathy, and symptomatic recurrence post-ablation.<\/span><\/div>\n
<\/div>\n
https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2836737<\/a><\/div>\n
<\/div>\n","protected":false},"excerpt":{"rendered":"

Early Rhythm Control (ERC) in Atrial Fibrillation \u2013 Evidence & Guideline Summary Source : JAMA Cardiol Published Online: July 30, 2025 1. Scientific Evidence \u2022 EAST-AFNET 4 Trial (NEJM 2020): \u2022 Enrolled patients with newly diagnosed AF (\u226412 months). \u2022 Compared Early Rhythm Control (ERC) (antiarrhythmic drugs, ablation, or cardioversion) vs Usual Care (mainly rate […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8396","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8396","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8396"}],"version-history":[{"count":2,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8396\/revisions"}],"predecessor-version":[{"id":8399,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8396\/revisions\/8399"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}